In silico analysis of Rutin and Morin against diabetes-associated molecular targets

Area of Science:

• Biochemistry
• Pharmacology
• Computational Biology

Background:

• Diabetes mellitus is a complex metabolic disorder with various therapeutic options.
• Current diabetes treatments can cause side effects like gastrointestinal issues and weight gain.
• Plant-derived compounds show antidiabetic potential, but their mechanisms require further study.

Purpose of the Study:

• To investigate the in-silico antidiabetic potential of Rutin (RU) and Morin (MO).
• To evaluate the efficacy of RU and MO against key enzymes and receptors implicated in diabetes.
• To explore the in-vitro inhibitory activity of RU and MO against diabetes-related molecular targets.

Main Methods:

• In-silico molecular docking simulations were performed for RU and MO against target enzymes and receptors.
• In-vitro enzymatic assays were conducted to assess the inhibitory activity of RU and MO.

Main Results:

• In-silico analysis indicated that RU and MO are effective inhibitors of diabetes-related enzymes (alpha-amylase, DPP-4, maltase-glucoamylase) and receptors (GLP-1R, SGLT1, SGLT2).
• The inhibitory potential of RU and MO was found to be comparable to or greater than conventional inhibitors.
• In-vitro assays confirmed the possible inhibitory activity of RU and MO against two diabetes-related molecular targets.

Conclusions:

• Rutin and Morin demonstrate significant potential as natural antidiabetic agents.
• These phytocompounds effectively target key molecular players in diabetes pathogenesis.
• Further research into RU and MO could lead to novel therapeutic strategies for diabetes management.